MedTrace Logo

Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00520676 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2011-08-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

pemetrexed

500 mg/m\^2, IV, q 21 days x 6 cycles maximum

DRUG

docetaxel

75 mg/m\^2, IV, q 21 days x 6 cycles maximum

DRUG

carboplatin

AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Australia
  • Brazil
  • China
  • Mexico
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520676 on ClinicalTrials.gov